Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARγ agonists

被引:52
作者
Cha, BS
Ciaraldi, TP
Park, KS
Carter, L
Mudaliar, SR
Henry, RR
机构
[1] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA
[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2005年 / 289卷 / 01期
关键词
type 2 diabetes mellitus; fatty acid oxidation; thiazolidinediones; mitochondria;
D O I
10.1152/ajpendo.00141.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The impact of type 2 diabetes on the ability of muscle to accumulate and dispose of fatty acids and triglycerides was evaluated in cultured muscle cells from nondiabetic (ND) and type 2 diabetic (T2D) subjects. In the presence of 5 mu M palmitate, T2D muscle cells accumulated less lipid than ND cells (11.5 +/- 1.2 vs. 15.1 +/- 1.4 nmol/mg protein, P < 0.05). Chronic treatment (4 days) with the peroxisome proliferator-activated receptor-gamma( PPAR gamma) agonist troglitazone increased palmitate accumulation, normalizing uptake in T2D cells. There were no significant differences between groups with regard to the relative incorporation of palmitate into neutral lipid species. This distribution was also unaffected by troglitazone treatment. beta-Oxidation of both long-chain (palmitate) and medium-chain (octanoate) fatty acids in T2D muscle cells was reduced by similar to 40% compared with ND cells. Palmitate oxidation occurred primarily in mitochondrial (similar to 40-50% of total) and peroxisomal (20-30%) compartments. The diabetes-related defect in palmitate oxidation was localized to the mitochondrial component. Both palmitate and octanoate oxidation were stimulated by a series of thiazolidinediones. Oxidation in T2D muscle cells was normalized after treatment. Troglitazone increased the mitochondrial component of palmitate oxidation. Skeletal muscle cells from T2D subjects express defects in free fatty acid metabolism that are retained in vitro, most importantly defects in beta-oxidation. These defects can be corrected by treatment with PPAR gamma agonists. Augmentation of fatty acid disposal in skeletal muscle, potentially reducing intramyocellular triglyceride content, may represent one mechanism for the lipid-lowering and insulin-sensitizing effects of thiazolidinediones.
引用
收藏
页码:E151 / E159
页数:9
相关论文
共 67 条
  • [1] Ceramide content is increased in skeletal muscle from obese insulin-resistant humans
    Adams, JM
    Pratipanawatr, T
    Berria, R
    Wang, E
    DeFronzo, RA
    Sullards, MC
    Mandarino, LJ
    [J]. DIABETES, 2004, 53 (01) : 25 - 31
  • [2] Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes
    Bahr, M
    Spelleken, M
    Bock, M
    vonHoltey, M
    Kiehn, R
    Eckel, J
    [J]. DIABETOLOGIA, 1996, 39 (07) : 766 - 774
  • [3] BHUIYAN AKMJ, 1994, BIOCHEM MOL BIOL INT, V34, P493
  • [4] Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle
    Blaak, EE
    Wagenmakers, AJM
    Glatz, JFC
    Wolffenbuttel, BHR
    Kemerink, GJ
    Langenberg, CJM
    Heidendal, GAK
    Saris, WHM
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2000, 279 (01): : E146 - E154
  • [5] The fate of [U-13C] palmitate extracted by skeletal muscle in subjects with type 2 diabetes and control subjects
    Blaak, EE
    Wagenmakers, AJM
    [J]. DIABETES, 2002, 51 (03) : 784 - 789
  • [6] MECHANISMS OF FATTY ACID-INDUCED INHIBITION OF GLUCOSE-UPTAKE
    BODEN, G
    CHEN, XH
    RUIZ, J
    WHITE, JV
    ROSSETTI, L
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (06) : 2438 - 2446
  • [7] Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects
    Boden, G
    Lebed, B
    Schatz, M
    Homko, C
    Lemieux, S
    [J]. DIABETES, 2001, 50 (07) : 1612 - 1617
  • [8] Regulation of fatty acid transport and membrane transporters in health and disease
    Bonen, A
    Luiken, JJFP
    Glatz, JFC
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2002, 239 (1-2) : 181 - 192
  • [9] Substrate utilization in non-obese Type II diabetic patients at rest and during exercise
    Borghouts, LB
    Wagenmakers, AJM
    Goyens, PLL
    Keizer, HA
    [J]. CLINICAL SCIENCE, 2002, 103 (06) : 559 - 566
  • [10] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3